Cannabis and WIN55
Browse the latest research linking medical marijuana / medicinal cannabis and WIN-55,212-2 (WIN55) (a cannabinoid (synthetic))

Action: CB1 agonist
WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure [Wikipedia]
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
WIN55 cancer,prostate cancer in vitro Cannabinoid WIN 55,212-2 induces endoplasmic reticulum stress in prostate cancer cells through CB1and CB2receptors Jul 2019
Our results reveal that treatment with 20mM WIN resulted in a significant reduction in the proliferation of DU145 and PC3 cells after 24 h compared to control (p<0.05).
WIN55,AM6545 weight loss,obesity in mice via experiment Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity Mar 2019
Action Pathway: CB1
Collectively, these results provide evidence that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-mediated inhibition of gut-brain satiation signaling.
WIN55,JWH-133 cancer,skin cancer in mice via experiment Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors Jan 2003
Action Pathway: CB2
Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice
JWH-015,WIN55 cancer,lung cancer in vitro Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis Nov 2010
Action Pathway: CB1,CB2
Furthermore, we have shown that the treatment of NSCLC cell lines (A549 and SW-1573) with CB1/CB2 and CB2-specific agonists Win55,212-2 and JWH-015, respectively, significantly attenuated random as well as growth factor-directed in vitro chemotaxis and chemoinvasion in these cells
WIN55 opioid in rats via experiment (n=30) Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats Apr 2011
Ingestion Method: intravenous
Action Pathway: CB1,opioid
Neutral  Our findings extend previous research on the crosstalk between cannabinoid and opioid receptors in relapse mechanisms, which suggests a differential role in heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.
WIN55 adhd in rats via expertiment The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Nov 2003
These results support the notion that a reduced cortical density of cannabinoid CB1 receptors is associated with enhanced impulsivity. This behavioural trait can be positively modulated by administration of a cannabinoid agonist. Present results confirm and extend previous literature, indicating that adolescent SHRs represent a suitable animal model for the preclinical investigation of the early-onset ADHD syndrome.
THC,WIN55,HU-210 cancer in vitro Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Mar 2004
Negative  Taken together, our data show that concentrations of THC comparable with those detected in the serum of patients after THC administration accelerate proliferation of cancer cells instead of apoptosis and thereby contribute to cancer progression in patients.
WIN55 cancer,prostate cancer in vitro Cannabinoid receptor as a novel target for the treatment of prostate cancer. Mar 2005
Our results suggest that WIN-55,212-2 or other non-habit-forming cannabinoid receptor agonists could be developed as novel therapeutic agents for the treatment of prostate cancer.
THC,WIN55 nausea in shrew Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew Jun 2007
Radiation-induced emesis (10 Gy) was blocked in a dose-dependent manner by the CB1/CB2-receptor agonists with the following ID50 potency order: CP55,940 (0.11 (0.09-0.12) mg/kg)>WIN55,212,2 (3.65 (3.15-4.23) mg/kg)=Delta8-THC (4.36 (3.05-6.22) mg/kg)>Delta9-THC (6.76 (5.22-8.75) mg/kg).
WIN55 cancer,glioma in vitro Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. May 2010
The present results demonstrate opposite changes in CB(1) and CB(2) receptor protein expression in human gliomas. These changes may be of interest for further research about the therapeutic effects of cannabinoids in glial tumors.
WIN55 adolescent use in mice via placebo trial Behavioral effects of chronic WIN 55,212-2 administration during adolescence and adulthood in mice. May 2019
Ingestion Method: 3.0 mg/kg/day WIN 55,212-2
For the reversal-learning task, there was no difference in errors or omissions to criterion following a reversal in adolescent-exposed mice but adult-exposed mice showed a delay in beginning the reversal, suggesting that adolescents, but not adults, are resilient to this drug. Adult mice given WIN 55,212-2 in adolescence displayed greater impulsivity in the form of preference for smaller-sooner reinforcers over larger-delayed ones in the delay-discounting procedure, but this was seen to a lesser extent with adult-onset exposure.